Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

Inclusion Criteria:

• For US : patients starting or planning to start or currently receiving treatmentwith Increlex® therapy for severe primary IGF-1 deficiency as defined by the USIncrelex® prescribing information or for growth hormone (GH) gene deletion who havedeveloped neutralizing antibodies to GH.For EU : patients starting or planning tostart or currently receiving treatment with Increlex® therapy according to thelocally approved product information.

• Parents or legally authorized representatives if applicable must give signedinformed consent before any registry-related activities are conducted. Assent fromthe subject should also be obtained as appropriate

Exclusion Criteria:

• Subject currently participating in an Increlex® clinical trial

• Subject currently participating in any clinical trial for growth retardation

• Patient with any contraindication to Increlex® or any condition subject to specialwarning as per the locally approved label

• For US patients, these include patients with hypersensitivity to the activesubstance or any of the excipients, patients with active or suspected neoplasia andpatients with closed epiphyses.

• For EU patients: these include patients with hypersensitivity to the activesubstance or any of the excipients, patients with active or suspected neoplasia orany condition or medical history which increases the risk of benign or malignantneoplasia and patients with closed epiphyses